Cytogenetic analysis in human bone marrow transplantation

• Published in: Cancer genetics and cytogenetics 1996-07, Vol.89 (1), p.21-26
• Main Authors: Ribeiro, Enilze M.S.F., Cavalli, Iglenir J., Schmid, Ana Teresa L., Cornélio, Déborah A., Tokutake, Alice S., Sperandio-Roxo, Valéria M.M., Rodriguez, Juan Manuel, Pasquini, Ricardo
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Anemia, Aplastic - genetics; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Biological and medical sciences; Bone Marrow Transplantation; Bone marrow, stem cells transplantation. Graft versus host reaction; Child; Chromosome Aberrations; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy; Male; Medical sciences; Middle Aged; Transfusions. Complications. Transfusion reactions. Cell and gene therapy
• ISSN: 0165-4608; 1873-4456
• DOI: 10.1016/0165-4608(95)00313-4

Bone marrow transplantation (BMT) is a therapeutic process used to treat a variety of hematologic diseases. After BMT, the documentation of engrafting with the use of genetic markers is obligatory. C-band polymorphism is an excellent genetic marker because it occurs with high frequency in all populations studied and shows a high stability in vitro and in vivo. We studied a total of 36 patients: 15 with myeloid leukemia and 21 with severe aplastic anemia (SAA), submitted to BMT. The majority of the patients with chronic granulocyte leukemia (CGL; 10/15, 67%) and with SAA (17/21, 81%) showed a frequency of host cells around 15% (CGL) and 8% (SAA) in the first period analyed (day +30 post-BMT); with a decrease in the others (+90, +180 to CGL and SAA and +365 only to CGL). In our study, the persistence of host cells in these proportions did not imply an unfavorable prognosis. On the contrary, some patients with myeloid leukemia (5/15, 33%) and SAA (4/21, 19%) showed high proportions of host cells in one or more periods analyzed. If compared to the first group, these patients had, in general, a poor clinical evolution, with rejections, relapses, and deaths in greater numbers. These results show the important contribution of cytogenetic analysis in the follow-up of patients submitted to BMT.